Peter Holleman
The complete DNA test allows for personalized treatment and so limits the chance of undesirable side effects.
Back to newsMore news
Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment
Researchers from Vall d’Hebron Institute of Oncology identify genomic signals predicting non-response to cancer therapies in collaboration with Hartwig Medical …
The starting point – always the patient
Frank van Wijck, science journalist Ele Visser is handing over his position as chairman of Hartwig Medical Foundation’s Data Access Board …
Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer …
The knowledge we gather with WGS can bring us a step closer to our goal to find an effective and suitable treatment for every single patient, not based on ‘one size fits all’, but adjusted to the characteristics of the patient and the tumor.